Epidemiological profile of 175 patients with Crohn's disease submitted to biological therapy

Journal of Coloproctology

Volumn 32, Issue 4, 2012, Pages 395-401

  Hardt, Marcelo Rassweiler ^a   Kotze, Paulo Gustavo ^a   Teixeira, Fabio Vieira ^b   Ludvig, Juliano Coelho ^c   Malluta, Everson Fernando ^d   Kleinubing Junior, Harry ^e   Miranda, Eron Fábio ^a   Tonini, Wanessa Bertrami ^a   Olandoski, Márcia ^f   Kotze, Lorete Maria da Silva ^f   Coy, Claudio Saddy Rodrigues ^g  

^a HOSPITAL UNIVERSITÁRIO CAJURU   (Brazil)

^b GASTROSAUDE Clinic   (Brazil)

^c Institute Espaço de Saúde do Aparelho Digestivo ESADI   (Brazil)

^d UNIVERSIDADE DO VALE DO ITAJAÍ   (Brazil)

^e UNIVERSITY OF JOINVILLE REGION   (Brazil)

^f PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^g UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Crohn's disease; Epidemiology; Tumor necrosis factor alpha

Indexed keywords

EID: 84879944271     PISSN: 22379363     EISSN: None     Source Type: Journal    
DOI: 10.1590/S2237-93632012000400006     Document Type: Article

References (21)

1. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95.
2. Souza MHLP, Troncon LEA, Rodrigues CM, Viana CFG, Onofre PHC, Monteiro RA, et al. Evolução da ocorrência (1980-1999) da doença de Crohn e da retocolite ulcerativa idiopática e análise das suas características clínicas em um hospital universitário do sudeste do Brasil. Arq Gastroenterol 2002;39(2):98-105.
3. Sedlack RE, Whisnant J, Elveback LR, Kurland LT. Incidence of Crohn's disease in Olmsted County, Minnesota, 1935-1975. Am J Epidemiol 1980;112(6):759-63.
4. Sonnenberg A. Geographic variation in the incidence of and mortality from inflammatory bowel disease. Dis Colon Rectum 1986;29(12):854-61.
5. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106(4):685-98.
6. Chaparro M, Panés J, García V, Merino O, Nos P, Domènech E, et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012;18(4):685-90.
7. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126(6):1593-610.
8. Wu EG, Mulani PM, Yu AP, Tang J, Pollack PF. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value Health 2008;11(5):820-9.
9. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4(1):28-62
10. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 (Suppl A):5-36.
11. Panaccione R, Loftus Jr EV, Binion D, McHugh K, Alam S, Chen N, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011;25(8):419-25.
12. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(1):52-65.
13. Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010;32(10):1228-39.
14. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9.
15. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350(9):876-85.
16. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58(4):492-500.
17. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140(6):1785-94.
18. Kotze PG, Vieira A, Sobrado Jr CW, Salem JB, Kotze LMS. Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series. J Coloproctol 2011;31(3):233-40.
19. Poli DD. Aspectos da raça e da ancestralidade na apresentação e evolução da DC no Brasil [Dissertação de Mestrado]. São Paulo: Faculdade de Medicina da Universidade de São Paulo; 2007. 51 p.
20. Souza MM; Belasco AGS; Aguilar-Nascimento JE. Perfil epidemiológico dos pacientes portadores de doença inflamatória intestinal do estado de Mato Grosso. Rev Bras Colo-proctol 2008;28(3):324-8.
21. Teixeira MG, Habr-Gama A, Takiguti CK, Brunetti Netto C, Pinotti HW. Aspectos epidemiológicos da doença de Cröhn em 140 pacientes do serviço de Colo-Proctologia do HCFMUSP. Rev Bras Colo-Proctol 1993;13(4):128-32.